Exergaming With Immersive Virtual Reality For People With Multiple Sclerosis (ExeRVIEM)

Sponsor
University of Vigo (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05870254
Collaborator
Asociación Viguesa de Esclerosis Múltiple de Pontevedra (Other)
18
1
2
2
9

Study Details

Study Description

Brief Summary

TITLE: Exergaming with Immersive Virtual Reality for people with Multiple Sclerosis

INTRO: Multiple Sclerosis (MS) is an autoimmune and chronic neurodegenerative pathology caused by loss of the myelin sheath in the nervous system, causing motor, cognitive, behavioral and sensory symptoms.

Conventional physiotherapy often includes exercise therapies, based on repetitive performances that can sometimes be unmotivating for patients. Immersive Virtual Reality could offer programs based on exercise (exergames) that are motivating, as well as appropriate to the therapeutic objectives of the target group. This tool has already been successfully tested in other groups (post stroke, Parkinson's,...) with promising results.

Our ExeRVIEM project (Exergaming with Immersive Virtual Reality in Multiple Sclerosis) represents a new strategy to improve functionality in people with MS, using an exercise program with Virtual Reality glasses.

HYPOTHESIS: The practice of the ExeRVIEM protocol based on physical function training in people with MS contributes to the maintenance and improvement of functional capacities, reducing the number of falls and increasing their personal autonomy.

GENERAL OBJECTIVES:

1.1 Design and implement an ExeRVIEM exercise program/protocol to improve balance in older people

1.2 Analyze the effects of this ExeRVIEM program/protocol, in the short and medium term in people who attend an Association of patients.

1.3 Identify if there is a relationship between the variables that induce frailty and functional dependence and the ExeRVIEM protocol.

SPECIFIC OBJECTIVES:

2.1 Determine and apply the ExeRVIEM protocol to explore differential effects for 6 minutes a day (2 days a week for 8 weeks).

2.1.1 Improving the functional independence and mobility of people by improving balance, reducing the risk of falls and the correct development of activities of daily living.

2.1.2 Gait improvement. 2.1.3 Improved functionality. 2.1.4 Improving grip strength. 2.1.5 Improving reaction times. 2.1.6 Improving the perception of fatigue

2.2 Determine the influence of parameters related to exposure to RVI.

2.2.1 Safety of the virtual reality exhibition 2.2.2 Usability of the virtual reality exhibition 2.2.3 Personal experiences and satisfaction of the virtual reality exhibition

METHODS:

Design: Randomized controlled trial. People diagnosed with MS who attend the AVEMPO VIGO center in Spain on a regular basis will be invited to participate in the study. After they meet the selection criteria, they will be assigned to an experimental group and a control group. Information on the sociodemographic characteristics and a clinical history of the participants will be collected.

Intervention: Two groups (experimental and control). The experimental group will carry out the ExeRVIEM protocol sessions (6 min) focused on the upper and lower limbs. (2 sessions per week for 8 weeks). All sessions will begin with a warm-up focused on stimulating coordination and joint mobilization, so that the body is predisposed both centrally and peripherally to carry out the session and will end with a stretching routine accompanied by breathing calm and controlled cycles. The session will be supervised by the center's physiotherapist or occupational therapist.

The control group will continue with the usual activities proposed by the center team.

Evaluations: 3 evaluations will be carried out: initial, final (at 8 weeks) and follow-up (one month after the end of the program).

The contents of the evaluations will be:

Patient characteristics: "Ad hoc" record sheet that will include data on age, sex, years since diagnosis, MS subtype, and drug treatment.

  1. ExeRVIEM protocol. Safety (Simulator Sickness Questionnaire), Usability (System Usability Scale) and personal experiences (Game Experience Questionnaire and "ad hoc" interview notebook)

  2. Balance, gait and risk of falling (Tinetti Test) 3. Functional mobility and lower limb strength (Five times sit to stand test) 4. Functional autonomy (Timed Up and Go Test- simple and cognitive) 5. Fatigue (Fatigue Severity Scale) 6 Handgrip (dynamometer) 7. Reaction time (Rezzil Software)

Hypothesis: Our findings aim to support the use of new health technologies in the field of rehabilitation and medical care for people with MS, achieving a feasible and safe Immersive Virtual Reality exergaming program.

Condition or Disease Intervention/Treatment Phase
  • Other: ExeRVIEM Program
  • Other: Usual center program
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
18 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Exergaming With Immersive Virtual Reality to Improve Functional Abilities in People With Multiple Sclerosis
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Jul 31, 2023
Anticipated Study Completion Date :
Aug 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: ExeRVIEM Protocol

They will carry out the ExeRVIEM program for 8 weeks (2 times a week). Intervention based on exercise therapies with RVI software.

Other: ExeRVIEM Program
Virtual exercise based program

Other: Usual center program
Usual center cares

Active Comparator: Usual Protocol

They will carry out the usual protocol of Association

Other: Usual center program
Usual center cares

Outcome Measures

Primary Outcome Measures

  1. Balance, gait and risk of falling [pre-intervention]

    TINETTI TEST

  2. Balance, gait and risk of falling [immediately after the intervention]

    TINETTI TEST

  3. Balance, gait and risk of falling [4 weeks after the intervention]

    TINETTI TEST

  4. functional autonomy [pre-intervention]

    TIMED UP GO

  5. functional autonomy [immediately after the intervention]

    TIMED UP GO

  6. functional autonomy [4 weeks after the intervention]

    TIMED UP GO

  7. functional and cognitive autonomy [pre-intervention]

    TIMED UP GO COGNITIVE

  8. functional and cognitive autonomy [immediately after the intervention]

    TIMED UP GO COGNITIVE

  9. functional and cognitive autonomy [4 weeks after the intervention]

    TIMED UP GO COGNITIVE

  10. functional mobility and lower limb strength [pre-intervention]

    Five Times Sit to Stand Test

  11. functional mobility and lower limb strength [immediately after the intervention]

    Five Times Sit to Stand Test

  12. functional mobility and lower limb strength [4 weeks after the intervention]

    Five Times Sit to Stand Test

  13. Reaction Time [pre-intervention]

    SOFTWARE REZZIL

  14. Reaction Time [immediately after the intervention]

    SOFTWARE REZZIL

  15. Reaction Time [4 weeks after the intervention]

    SOFTWARE REZZIL

  16. Fatigue [pre-intervention]

    The Fatigue Severity Scale

  17. Fatigue [immediately after the intervention]

    The Fatigue Severity Scale

  18. Fatigue [4 weeks after the intervention]

    The Fatigue Severity Scale

Secondary Outcome Measures

  1. Safety of the IVR intervention [immediately after the intervention]

    Simulator Sickness Questionnaire

  2. Usability of the IVR intervention [immediately after the intervention]

    System Usability Scale

  3. Satisfaction and experiences post IVR intervention [immediately after the intervention]

    Game Experience Questionnaire-POST GAME MODULE

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • People diagnosed with MS belonging to the AVEMPO VIGO Association

  • Ages between 18-65 years

  • Ability to stay on your feet and follow the intervention protocol and scheduled assessments

Exclusion Criteria:
  • Medical report that advises against the practice of physical activity and exercise

  • Uncontrolled outbreak of the disease

  • Dizziness, vertigo or severe visual impairment.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Pablo Campo-Prieto Pontevedra Galicia Spain 36005

Sponsors and Collaborators

  • University of Vigo
  • Asociación Viguesa de Esclerosis Múltiple de Pontevedra

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pablo Campo-Prieto, Principal Investigator, University of Vigo
ClinicalTrials.gov Identifier:
NCT05870254
Other Study ID Numbers:
  • HEALTHYFIT-UVIGO 1/2023
First Posted:
May 23, 2023
Last Update Posted:
May 23, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 23, 2023